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http:WHAT THIS PAPER ADDS
The results of endoscopic vein harvesting (EVH) have been widely reported in cardiothoracic surgery, but evi-
dence for EVH in peripheral arterial bypass surgery has not been subjected to systematic review. We aim to
identify areas in which further research is required in order to establish the most appropriate method of vein
graft harvest to use in clinical practice.Objective: Endoscopic vein harvesting (EVH) for arterial bypass surgery may be associated with lower wound
complication rates than open vein harvesting (OVH), but other long-term outcomes remain controversial, and
there are concerns that graft patency may be poorer after EVH compared with OVH. We conducted a systematic
review of all available evidence for EVH in lower extremity arterial bypass (LEAB).
Methods: A literature search of Medline, Embase, Ovid and Cochrane databases between 1996 and 2013 was
performed using the terms “endoscopic vein harvesting”, “minimally invasive vein harvest”, “peripheral bypass
surgery”, and “lower extremity bypass surgery”, and detailed in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses. Primary outcomes were graft patency and overall wound complication
rates. Secondary outcomes were wound infection, length of hospital stay, and cost-effectiveness. Summary
estimates were calculated by random effects meta-analysis if sufﬁcient data were available.
Results: We identiﬁed 18 cohort studies and case series, with considerable clinical heterogeneity, including 2,343
patients. Meta-analysis of six studies revealed a signiﬁcantly reduced rate of primary patency after EVH (hazard
ratio 1.29, 95% conﬁdence interval [CI] 1.03e1.63), with no signiﬁcant difference between EVH and OVH with
respect to wound infection in 12 studies (odds ratio 0.81, 95% CI 0.61e1.08). There was a lack of strong evidence
to support the secondary outcomes of EVH.
Conclusion: EVH reduces primary patency rates after LEAB, but does not demonstrate an advantage with respect
to postoperative wound complications. However, the available data are heterogeneous, and uncertainty is
introduced by both evolution in technology and increasing technical experience. EVH should be used with caution
and in the context of formal research.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Wound healingINTRODUCTION
Despite considerable advances in endovascular techniques
for lower limb revascularisation in peripheral arterial dis-
ease (PAD), lower extremity arterial bypass (LEAB) remains
the optimum therapy for many patients.1,2 Autologous vein
is preferred, with better long-term patency, particularly for
below-the-knee intervention.3 Conventionally, open vein
harvest (OVH) involves either one long incision, or ‘bridged’se authors contributed equally to this work.
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//dx.doi.org/10.1016/j.ejvs.2014.02.009incisions along the length of the vein; disadvantages include
wound infection, dehiscence, and pain, contributing to
greater costs from prolonged hospital stay or readmissions.4
Alternatively in situ bypass may be performed, negating the
need for any vein harvest. In patients with PAD, wound
complications may be exacerbated by underlying athero-
sclerotic disease or diabetes mellitus.5e7
Minimally invasive endoscopic vein harvest (EVH) was
ﬁrst reported in cardiothoracic surgery in 1996 as an
alternative to OVH.8 An endoscope is introduced adjacent
to the vein, allowing its dissection under direct vision via 1e
2 small incisions, sometimes aided by insufﬂation of carbon
dioxide (CO2) to aid visualisation. Over the last decade, EVH
has become the preferred technique for conduit harvest in
many cardiothoracic centres owing to the overall reduction
in complications compared with OVH.9e11 However,
15
622 Y.A. Jauhari et al.concerns persist regarding the risk of microscopic damage
incurred during EVH, and the consequences of this for long-
term graft patency.12e14
In peripheral arterial surgery, the use of EVH for conduit
harvest is still novel, and deﬁnitive evidence is lacking to
encourage its wider adoption or to guide further research.
This study presents a systematic review to summarise the
evidence for EVH in LEAB.Figure 2. Summary of 2011 Levels of Evidence with respect to
our question.METHODS
The primary outcomes for this study were the incidence of
wound complications and graft patency in LEAB performed
using EVH or OVH. Secondary outcomes included limb
salvage, duration of procedure and hospital stay, and cost-
effectiveness.
An electronic search was performed using the Embase,
MEDLINE, and Cochrane databases for the period between
January 1996 and December 2013. The free-text search
terms “endoscopic vein harvesting”, “minimally invasive
vein harvest”, “peripheral bypass surgery”, and “lower ex-
tremity bypass surgery” were used in conjunction with
controlled vocabularies where available (see Fig. 1 for the
MEDLINE search strategy). Trial registers on the internet and
abstracts from vascular surgery meetings were also
searched to locate unpublished work. The inclusion criteria
were deﬁned as studies of EVH for LEAB that reported at
least one primary or secondary outcome measure. This
included non-comparative observational and grey literature
(unpublished studies and abstracts). Exclusion criteria
comprised studies that did not exclusively utilise EVH in
“minimally invasive vein harvesting”, were not published in
English or were commentary/review articles. Two reviewers
(Y.J. and C.H.) independently extracted outcomes data
and graded each study in accordance with the Oxford
Centre for Evidence-Based Medicine 2011 Levels of Evi-
dence (see Fig. 2).15
Data were extracted regarding study characteristics, case
selection, and LEAB outcome (Tables 1e4). The mean value
was used for all continuous outcomes, and derived from
median data, where necessary, using an established tech-
nique.16 Comorbidities were categorised dichotomously as
cerebrovascular, cardiovascular, hypertensive, and respira-
tory disease; renal failure; diabetes; hyperlipidaemia; and
smoking history. Both single and bridged incisions tech-
niques were considered to be OVH. Surgery was categorisedFigure 1. PubMed searchas either above (AK) or below knee (BK) LEAB based on the
distal target vessel in each case. Therefore, bypasses with
BK inﬂow and outﬂow vessels were also deﬁned as BK LEAB.
For consistency in reporting primary outcomes, wound
complications were classiﬁed using the Szilagyi method
whereby class I wounds were erythematous requiring an-
tibiotics, class II were draining/superﬁcial dehiscence, and
class III wounds exposed or compromised the bypass
grafts.17 Patency was recorded according to reporting
standards:18 primary patency described grafts that required
no intervention; primary assisted patency for grafts that
required prophylactic interventions; and secondary patency
were grafts that required deﬁnitive surgical or radiological
salvage to maintain patency. Where necessary, patency was
estimated from graphs.19e21 Random effects meta-analysis
of primary patency and wound complication data was
performed using metan22 version 9 in StataSE 12.1 (Stata-
Corp, College Station, TX, USA). Statistical heterogeneity
was assessed using Cochran’s Q test and reported using the
I2 statistic. Wound complication rates were extracted from
each study and grouped as a composite outcome measure,
and meta-analysed by the Mantel and Haenszel method.
A meta-analysis of the hazard ratio (HR) of loss of primary
patency was undertaken using the inverse variance random
effects method. Summary time-to-event data (loge(HR), SE
[loge(HR)], variance and observed expected events) was
calculated using KaplaneMeier curves for papers not
reporting these data numerically using the methods out-
lined by Tierney et al.23RESULTS
The literature search identiﬁed 236 studies, of which 25 met
the inclusion criteria for review. Seven studies were
excluded because EVH was used in combination withof MEDLINE database.
Table 1. Summary of demographics and case selections of the studies included in this review. Results are presented as endoscopic vein harvest (EVH) versus open vein harvest (OVH).
Study OCEBM
2011 LoE15
Patients
(n)
EVH vs.
OVH
Mean
follow-up
(mo, range)
Age (y, median
or mean and
range)
% Male Patient
comorbidities
Indication
for LEAB
Type of LEAB Conduit
harvest
Santo
et al. (2014)41
3 351 98 vs. 153 24.58
(5.8e66.5)
vs. 26.1
(7.75e77.5)
65.7  9.8 vs.
66.7  13.7
94 vs. 60 Cardiovascular
42.9% vs. 40.5%,
hypertension
78.6% vs. 81.7%,
hypercholesterolaemia
41.8% vs. 39.2%,
diabetes 53.1% vs.
50.3%, dialysis
13.3% vs. 14.4%,
active smokers 48%
vs. 36.6%, ex-smoker
34.7% vs. 39.2%
Critical limb
ischaemia
AK LEAB
8.2% vs.
13.1%, BK
LEAB 91.8%
vs. 86.9%
LSV
Wartman
et al. (2013)33
3 76 35 vs. 41 62.25 72 vs. 67 66 vs. 61 Cerebrovascular
9.0% vs. 32.0%
(p ¼ .01),
cardiovascular
51.0% vs. 56.0%,
hypertension
86.0% vs. 85.0%,
hypercholesterolaemia
60.0% vs. 49.0%,
diabetes 49.0% vs.
63.0%, renal failure
11.0% vs. 29.0%
(p ¼ .06), smokers
26.0% vs. 20.0%
Unknown AK LEAB
40.0% vs.
34.0%
(NS),
BK LEAB
60.0% vs.
66.0%% (NS)
LSV
Eid et al.
(2012)34
3 88 39 vs. 49 22.8 Unknown Unknown Unknown Critical limb
ischaemia
Unknown Unknown
Julliard
et al.
(2011)20
3 363 170 vs. 193 35 (3e105) 67.8 vs.
65.0 (NS)
64.5 vs.
69.9 (NS)
Cerebrovascular
13.0% vs. 5.7%
(p [ .02),
cardiovascular
46.7% vs. 44.5%
(NS), hypertension
81.7% vs. 76.2%
(NS), renal failure
22.5% vs. 24.3%
(NS), NIDDM 25.4
vs 16.1% (p [ .03),
IDDM 32.0% vs.
28.5% (NS),
Claudication
33.7% vs. 22.8%
(p [ .03), rest
pain 18.9% vs.
16.1% (NS),
ulcer
24.9% vs. 26.4%
(NS), gangrene
20.7% vs. 23.3%
(NS), aneurysm
4.7% vs. 8.8%
(NS), trauma
0.6% vs. 7.3%
AK fem-pop
22.5% vs.
21.2% (NS),
BK fem-pop
24.9% vs.
26.9% (NS),
femoro-
tibial 29.6%
vs. 33.2%
(NS),
popliteo-tibial
22.5% vs.
17.6% (NS),
LSV
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Table 1-continued
Study OCEBM
2011 LoE15
Patients
(n)
EVH vs.
OVH
Mean
follow-up
(mo, range)
Age (y, median
or mean and
range)
% Male Patient
comorbidities
Indication
for LEAB
Type of LEAB Conduit
harvest
hyperlipidaemia
35.5% vs. 35.2%
(NS), active smokers
29.6% vs. 33.2%,
ex-smokers >10 y
11.2% vs. 5.7%
(p [ .001),
other 3.0%
vs. 4.7% (NS)
ilio-tibial
0.6% vs.
0% (NS)
Hines
et al. (2010)45
4 27 NA 22.7 66.6  8.2 51.9 Cardiovascular
50.0%, hypertension
65.0%,
hypercholesterolaemia
69.0%, diabetes 54.0%,
smokers 65.0%
TASC-D SFA
lesions; 37.0%
claudicants,
30.0% rest
pain, 33.0%
tissue loss.
11.1% re-do
of prosthetic
bypasses
AK LEAB
44.4%, BK
LEAB 55.6%
LSV
Jimenez et al.
(2007)42
4 13
(14 limbs)
NA 5 (1e19) 62.7  10.3 61.5 Cerebrovascular
23.1%, cardiovascular
15.4e69.2%,
hypertension
92.3%, IDDM 61.5%,
renal failure 23.1%,
smoking history
38.5% (pack years
37.0  11.3)
Rest pain
85.7%,
tissue loss
57.1%,
popliteal
aneurysm
14.3%;
38.5% re-do
LEAB
AK LEAB 7.1%,
BK LEAB 92.9%
LSV
Pullatt
et al. (2006)21
3 324 85 vs. 239 OVH:
single 33  35,
bridged 18  21,
EVH: 17  21
63  15 vs.
63e65  15
(NS)
56 vs. 70e73
(p [ .02)
Cardiovascular
38.0 vs
.25.0e32.0%
(NS), hypertension
82.0% vs. 71.0%
(NS), diabetes
56.0% vs.
55.0e57.0%
(NS), smokers
62.0% vs. 39.0e
40.0% (p [ .001)
Claudication
5.0 vs. 5.0e
8.0% (NS),
rest pain
28.0% vs.
28.0e29.0%
(NS), ulcer
16.0% vs.
15.0e19.0%
(NS), gangrene
51.0% vs.
44.0e52.0% (NS)
Fem-pop
32.0% vs.
20.0e43.0%
(p < .001),
fem-tibial/
pedial 51.0
vs. 31.0%e
41.0%
(p [ .024),
pop-tibial/
pedal
18.0% vs.
25.0e40.0%
(p [ .001)
LSV
Trotter
et al. (2006)35
3 65 26 vs. 39 8 (1e24) 69 65 Cardiovascular 53.8%,
hypertension 96.0%,
diabetes 69.2%,
Claudication
11.5%, rest
pain 19.2%,
FemeAK-pop
15.4%; fem
-BK-pop
LSV
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Table 1-continued
Study OCEBM
2011 LoE15
Patients
(n)
EVH vs.
OVH
Mean
follow-up
(mo, range)
Age (y, median
or mean and
range)
% Male Patient
comorbidities
Indication
for LEAB
Type of LEAB Conduit
harvest
CKD on dialysis
11.5%, smoking
69.2%,
hypercholesterolaemia
57.7%
tissue loss
38.4%, CLI
30.8%; 23.0%
had previous
operations
26.9%;
fem-TP 3.8%;
femoral-PT
15.4%; fem-
peroneal
7.7%;
femoral-AT
3.8%;
SFA-AT 3.8%;
SFA-DP 3.8%;
AK pop-AT
3.8%; BK
pop-DP 7.7%;
BK pop-PT
3.8%;
BK pop-plantar
artery 3.8%
Gazoni
et al. (2006)19
3 88 29 vs. 59 21 64.9  12 vs.
62.4  11.9
(NS)
82.3 vs.
83.5 (NS)
Diabetes 44.8% vs.
50.9% (NS),
hypertension
93.1% vs. 83.1%
(NS), smokers
44.8 vs. 50.9 (NS)
Claudication
28.0e30.0%
(NS), rest pain
14.0% (NS),
limb salvage
48.0e49.0%
(NS), aneurysm
5.0e10.0% (NS),
trauma 1.7% (NS),
re-do operations
20.7% vs. 20.3%
(NS)
100% BK LEAB LSV
Erdoes
et al. (2005)27
3 197
(214 limbs)
NA 18 (1e48) 76.2 (39.0e98.0) 63.4 Cardiovascular 61.4%,
hypertension 77.2%,
renal failure 33.0%
(dialysis-dependent
11.7%), diabetes 68.0%,
smokers 46.2%,
hyperlipidaemia 69.5%
Tissue loss 71.0%,
rest pain 17.3%,
claudication 9.3%,
aneurysm 1.9%,
trauma 0.5%
AK LEAB
86.6%, BK
LEAB 16.4%
(note: 9.8%
multi-level
reconstruction
using stent
[n ¼ 2] or
proximal
prosthesis
[n ¼ 3])
LSV 98.1%,
SSV 1.9%
3 227 61 vs. 69 (NS) LSV
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Table 1-continued
Study OCEBM
2011 LoE15
Patients
(n)
EVH vs.
OVH
Mean
follow-up
(mo, range)
Age (y, median
or mean and
range)
% Male Patient
comorbidities
Indication
for LEAB
Type of LEAB Conduit
harvest
Illig et al.
(2003)39
99 (108 limbs)
vs. 128
(134 limbs)a
68.5  13.9 vs.
68.9  16.2
(NS)
Diabetes 42% vs.
47% (NS)
Claudication
17.0% vs. 14%
(NS), limb
salvage
80.0% vs.
82.0% (NS),
open
wound/
gangrene
50.0% vs.
43.0% (NS)
Femoro-
popliteal
40.0% vs.
33.0%, femoro-
tibial 37.0% vs.
50.0%, popliteo-
tibial 19.0% vs.
14.0%, femoral-
popliteal-tibial
composite 4.0%
vs. 2.0%, in
situ LEAB 0%
vs. 18.0%
(p < .005)
Suggs
et al. (2001)40
3 50 25 vs. 25 18 (6e30) 67  14 vs.
69  13
52 vs. 56 Cardiovascular:
previous CABG
20.0% vs. 16.0%;
CCF 16.0% vs. 12.0%,
diabetes 56.0% vs.
64.0%, respiratory
12.0% vs. 16.0%,
renal failure
4.0% vs. 4.0%
Rest pain
44.0% vs.
40.0%,
gangrene
56.0% vs.
60.0%
Fem-PT
44.0% vs.
48.0%,
femoro-
peroneal
44.0% vs.
36.0%,
fem-DP
8.0% vs.
8.0%,
fem-AT
4.0% vs.
4.0%
LSV
Jordan Jr
et al. (2001)44
4 150 NA 1e73 62 (44e89) 74 Cardiovascular 43.0%,
hypertension 69.0%,
diabetes 43.0%,
smoking history
75.0%,
hyperlipidaemia
28.0%, renal
failure/transplant
10.0%
Critical
limb
ischaemia
72.6%,
claudication
23.2%,
popliteal
aneurysms
4.3%
AK LEAB
24.4%,
BK LEAB
75.6%
LSV
Illig et al.
(2001)36
3 110 61 vs. 49a <15 70 - 11 vs.
67  13 (NS)
Unknown Unknown Claudication
25.0% vs.
20.0% (NS),
limb salvage
Femoro-
popliteal
46.0% vs.
29.0% (NS),
femoro-tibial
LSV
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Table 1-continued
Study OCEBM
2011 LoE15
Patients
(n)
EVH vs.
OVH
Mean
follow-up
(mo, range)
Age (y, median
or mean and
range)
% Male Patient
comorbidities
Indication
for LEAB
Type of LEAB Conduit
harvest
80.0% vs.
75.0% (NS)
33.0% vs.
45.0% (NS),
femoral-
popliteal-tibial
composite
8.0% vs. 12.0%
(NS), popliteal-
tibial 13.0% vs.
14.0% (NS), in
situ LEAB 0%
vs. 6.0% (NS)
Johnson et al.
(1998)38
3 32 16 vs. 16 7 70.5 9.5 vs.
74.0  14.1
68.7 vs. 56.2 Unknown Unknown AK fem-pop
6.2% vs. 18%,
BK fem-pop
62.5% vs.
43.7%,
fem-PT/
peroneal
31.2% vs.
37.5%
LSV
Robbins
et al. (1998)37
4 64 33 (34 limbs)
vs. 28
(30 limbs)
<12 70.0  10.9
vs. 73.9  9.3
57.6 vs. 64.3 Unknown Tissue loss
38.2% vs.
36.7% (NS),
claudication
23.5% vs.
26.7% (NS),
micro-emboli
0% vs. 3.3%
(NS), popliteal
aneurysm
2.9% vs.
3.3% (NS)
AK 12.0%
vs. 17.0%,
BK 73.0%
vs. 70.0%,
distal tibial/
pedal 15.0%
vs. 13.0%
LSV
Jordan Jr
et al. (1997)43
4 65
(68 limbs)
NA 7.9
(1.0e24.0)
60.5
(39.0e89.0)
86 85% current or
ex-smoker, 37.0%
diabetes
Tissue loss
47.7%,
claudication
16.9%,
rest pain
35.4%,
popliteal
aneurysm
4.6%
AK LEAB
23.5%, BK
femoral-
popliteal
44.1%,
femoral
tibial/
peroneal
32.4%
LSV
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628 Y.A. Jauhari et al.laparoscopic or other techniques for vein harvest,24,25 or for
coronary artery bypass surgery (CABG) and LEAB;26 were
commentary or review articles;27e30 or were published as
full-text, non-English articles.31 One presentation abstract32
was also excluded as the results were further published as a
research paper.33 There were no randomised control
studies, and 12/18 were single-centre comparative (cohort)
studies.19e21,33e41 Only one of these was a prospective
design.42 The level of evidence ranged from 3 to 4, inclusive
of one abstract from a conference presentation (Fig. 3).34
Study characteristics (Table 1)
From 2,343 cases, 752 EVH conduits (bypasses) were re-
ported in 742 patients over a weighted mean follow-up of
27 months (range 1e105 months). The majority of patients
were men (1,189/1,830), with a mean (standard deviation
[SD]) age ranging from 63 (15) to 72 (9) years.
Atherosclerosis-related comorbidities, such as hypertension
(78.0%); smoking history (54.0%); diabetes mellitus (49.0%);
and cardiovascular disease (44.0%) were common. Among
the comparative studies, there was a signiﬁcantly higher
rate of cerebrovascular disease alone in Wartman et al.,33
cerebrovascular disease and diabetes in Julliard et al.,20
and smokers in Pullatt et al.21 in the EVH group compared
with the OVH group.
Case selection (Table 1)
Preoperative LEAB vein mapping was always performed in
9/18 studies,33,35,36,39e43 occasionally in 3/18,27,44,45 never
in 2/18,19,21 and was not declared in 4/18 studies.20,34,37,38
All studies utilised either the long or short saphenous vein
as the conduit of choice, with the exception of Eid et al.,34
who did not specify the conduit used. The selection of pa-
tients for EVH was largely based on surgeon preference or
the availability of equipment. Common exclusion criteria for
EVH included the presence of previous trauma, the use of
composite grafts, or the presence of short segments of vein
or arm veins. Two separate papers by Illig et al.36,39 included
composite grafts in the EVH cohort. Four of 18 studies re-
ported in situ EVH for LEAB.38e40,44
Operative techniques (Table 2)
There was considerable variation in EVH equipment and
technique between studies. This included the use of balloon
rather than CO2 insufﬂation to produce a tunnel for vein
harvesting20,33,36,38,39 and use of light compression
bandaging after vein harvest to prevent haematomas.19,36,39
The latter practice was actively discouraged by other studies
owing to increased risk of limb ischaemia in patients with
peripheral vascular disease or compromising in situ LEAB
grafts.42
EVH was used in 57 AK and 469 BK LEAB (in 106 femoral-
popliteal bypasses AK/BK was not speciﬁed). The most
common indications for LEAB were claudication (5.0e
37.0%), rest pain (14.0e100.0%), tissue loss (16.0e57.1%),
popliteal aneurysms (2.9e14.3%), and re-do LEAB (0e
38.5%). Two studies focused solely on the use of EVH in
Table 2. Summary of operative techniques of the studies included in this review. Results are presented as endoscopic vein harvest (EVH) versus open vein harvest (OVH).
Study OVH method EVH equipment Tunnel method Conduit harvest EVH criteria Surveillance method
and interval
Santo et al. (2014)41 All cases Single incision Vasoview (Maquest,
Rassatt, Germany)
Unknown Several vascular surgeons Surgeon preference
(single-length LSV)
Wartman et al. (2013)33 Intraoperative
in all cases
Single incision Maquet Vasoview
(Maquet Cardiovascular,)
Balloon-produced tunnel One vascular surgeon (OVH ¼
several surgeons)
LEAB requiring single
segment LSV only
Eid et al. (2012)34 Unknown Unknown Unknown Unknown Unknown Unknown
Julliard et al. (2011)20 Unknown Endosaph, Coviden
(Mansﬁeld, MA, USA)
Balloon One surgeon (OVH ¼
several surgeons)
Equipment availability and
surgeon preference
Duplex USS: year
1 ¼ 3 monthly,
year 2 ¼ 6 monthly,
yearly thereafter,
lifelong
Hines et al. (2010)45 NA Vaso View (Guidant
Cardiac and Vascular
Surgery, Menlo Park,
CA, USA)
CO2 insufﬂation One cardiac surgical
physicians assistant
EVH excluded in poor vein
quality or previous use
of vein for bypass
Duplex USS: year
1 ¼ 3, 6, 9, and
12 months; then
6-monthly thereafter
Jimenez et al. (2007)42 NA Vaso View 7 (Guidant,
Indianapolis, IN, USA)
CO2 insufﬂation Several surgeons Surgeon preference Unknown
Pullatt et al. (2006)21 Single or bridged
incisions
Cardioversion (Ethicon
Endo-surgery, Johnson
& Johnson, Cincinnati,
OH, USA)
CO2 insufﬂation One surgeon (OVH ¼
several surgeons)
Surgeon preference Duplex USS:
3 and 12 months,
yearly thereafter
Trotter et al. (2006)35 Unknown Unknown Unknown Surgical physicians
assistant
Surgeon preference Unknown
Gazoni et al. (2006)19 Bridged incisions Vaso View 6 (Guidant
Cardiac and
Vascular Surgery)
CO2 insufﬂation Several cardiac
physicians assistants
for EVH and OVH
Equipment availability Unknown
Erdoes et al. (2005)27 NA Vaso View (Guidant) CO2 insufﬂation Several cardiac
physicians assistants
(LEAB by one surgeon)
EVH excluded in arm vein,
use of prosthesis, or short
segment bypass with vein
through arterial exposure
Duplex USS: year
1 ¼ 3 monthly,
year 2 ¼ 6
monthly, yearly
thereafter
Illig et al. (2003)39 Single or bridged
incisions
Endosaph, United
States Surgical
(Norwalk, CT, USA)
Balloon Single surgeon Surgeon preference Unknown
Suggs et al. (2001)40 NA Endopath (Ethicon,
Somerset, NJ, USA)
Unknown Several surgeons Unknown Duplex USS: 1, 3,
and 6 months,
then 6-monthly
intervals thereafter
Jordan Jr et al. (2001)44 NA Endoscopic saphenous
vein harvest tray
(Ethicon Endosurgery)
Unknown Unknown Elective LEAB using LSV
conduit (vein length >15 cm)
Duplex USS:
year 1 ¼ 1 week,
3, 6, and 12 months,
6e12 month
intervals thereafter
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Table 2-continued
Study OVH method EVH equipment Tunnel method Conduit harvest EVH criteria Surveillance method
and interval
(but grafts deemed
high thrombosis risk
had more
frequent surveillance)
Illig et al. (2001)36 Unknown Endosaph, United
States Surgical
Balloon-produced
tunnel
Single surgeon Surgeon preference: no acute
ischaemia or trauma, LSV
2.8e3.0 mm in
preoperative mapping
Unknown
Johnson et al. (1998)38 Unknown Vaso View Balloon
Dissection System
(Origin Medsystems,
Menlo Park, CA, USA)
Balloon and CO2
insufﬂation
Several surgeons Unknown Unknown
Robbins et al. (1998)37 Unknown Endopath (Ethicon
Endosurgery)
Unknown Single surgeon EVH excluded in
re-do operations,
contralateral
vein harvest
and use of
composite grafts
Unknown
Jordan Jr et al. (1997)43 NA Endoscopic
saphenous vein
harvest tray (Ethicon
Endosurgery)
Unknown Unknown Unknown Duplex USS: year
1 ¼ 1 week, 3, 6,
and 12 months,
6e12 month
intervals
thereafter
(but grafts
deemed high
thrombosis risk
had more
frequent
surveillance)
Y.A. Jauhari, C.O. Hughes,
S.A. Black, K.G. Jones,
R.J. Hinchliffe, M.M.
Thompson, P.J. Holt, A.
Karthikesalingam
(unpublished)
Bridged incisions Vasoview Haempro
(MAQUET Cardiovascular,
Wayne, NJ, USA)
CO2 insufﬂation Several surgeons Surgeon
preference
Duplex USS: 6
weeks; 3, 6, 12,
18 and then
24 months
Note. NA ¼ not applicable; CO2 ¼ carbon dioxide; LEAB ¼ lower extremity arterial bypass; LSV ¼ long saphenous vein; USS ¼ ultrasound scan.
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Table 3. Summary of operative techniques of the studies included in this review. Results are presented as endoscopic vein harvest (EVH) versus open vein harvest (OVH).
Study Wound complications Primary patency Primary assisted patency Secondary patency
Santo et al. (2014)41 Overall: 36.7% vs. 44.4%
(NS); vein harvest incision
complication: 11.8% vs
29.1% (p [ .02)
12 months: 58.0% vs. 71.0%;
36 months: 41.0% vs. 52.0%
(p [ .010)
12 months: 88.0% vs. 88.0%;
36 months: 71.0% vs.
64.0% (p ¼ .266)
Wartman et al. (2013)33 30-day: 29.0% vs.
27.0% (NS)
36 months: 47.0% vs.
49.0% (NS)
36 months: 88.0% vs. 76.0% (NS) 36 months: 92.0% vs.
73.0% (p ¼ .53)
Eid et al. (2012)34 Vein harvest site: 0% vs.
20.0% (all sites 16.2%
vs. 22.9% [NS])
12 months: 43.2% vs.
69.4% (p [ .007)
Re-interventions per bypass graft:
1.28 vs. 0.37 (p < .001)
Julliard et al. (2011)20 Type I: 11.2% vs. 11.4%
(NS); type II: 3.6% vs.
4.7% (NS); type III:
3.6% vs. 4.1% (NS);
re-opening 10.1%
vs. 8.8% (NS)
36 months: 40.0% vs. 60.0%
(p < .05). In LEAB for critical
limb ischaemia: 26.0% vs.
58.0% (p < .001); LEAB in
non-diabetics: 54.0% vs.
64.0% (NS); LEAB in
diabetics: 22.0% vs.
44.0% (p < .01)
36 months: 50.0% vs. 68.0%
(p < .01)
36 months: 58.0%
vs.70.0% (p < .05)
Hines et al. (2010)45 Class I: 3.7% 12 months: overall
73.2% (maintained
at 70 months).
Subgroups: 80.0% for
claudication, 75.0% for
rest pain, 64.8% for
tissue loss.
12 months: overall 80.8% (maintained
at 70 months). Subgroups: 80% for
claudication, 87.5% for rest pain,
77.8% for tissue loss
Unknown
Jimenez et al. (2007)42 None 30 days: 85.7%;
overall: 92.9%
63.6% 3/14 (21.0%)
Pullatt et al. (2006)21 Class IeII: 6.0%
vs. 9.0e10% (NS)
60 months: EVH 33.0% vs.
single OVH 59.0%
(p [ .004), single
OVH 59 vs. bridged
OVH 44 (NS)
Unknown 60 months: EVH 47 vs.
single OVH 66.0%
(p [ .046), single OVH
66.0% vs. bridged OVH
58.0% (NS)
Trotter et al. (2006)35 Class II: 1; class III: 2 At 6 months: 92%
Gazoni et al. (2006)19 Overall wound
complications:
13.8% vs. 16.9%
(NS); wound infections:
3.4% vs. 15.3%
(NS), 3 OVH haematoma
21 months: 92.8%
vs. 80.6% (NS)
21 months: 96.4% vs. 86.0% (NS) 21 months: 96.5% vs.
96.5%
Erdoes et al. (2005)27 7.5% (class IeIII),
2.5% requiring
readmission
18 months: 71.5% 18 months: 77.2%
Illig et al. (2003)39 Overall: 20.4% vs. 34.1%
(NS); type I: 11.2%
Overall 1 month: 92.0%
vs. 91.0% (NS), LEAB for
Unknown Unknown
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Table 3-continued
Study Wound complications Primary patency Primary assisted patency Secondary patency
vs. 13.5% (NS); type II:
6.5% vs. 15.%; type III:
2.8% vs. 4.8% (NS);
haematoma: 6.5% vs.
8.7% (NS); seroma:
6.4% vs. 10.9% (NS);
acute re-exploration:
2.8% vs. 0% (NS);
re-admission for
wound complication:
4.1% vs. 11.4%
claudicationd30 days:
95.0% vs. 100.0% (NS),
12 months: 88.0% vs.
82.0% (NS), 24 months
88.0% vs. 82.0% (NS);
LEAB for limb salvage
at 1 month: 92.0%
vs. 89.0% (NS),
60.0% vs. 64.0%
(NS), 49.0% vs.
61.0% (NS)
Suggs et al. (2001)40 4.0% (n ¼ 1) vs.
20.0% (n ¼ 5)
12 months: 91.0 
4.0% vs. 92.0  5.0%
Unknown Unknown
Jordan Jr et al. (2001)44 30-day: 8.5% (type IeII) 30 days: 90.5%,;12
months: 68.9%; 60
months: 51.4%
30 days: 91.7%; 12 months:
79.5%; 60 months: 63.6%
60 months: 68.0%
Illig et al. (2001)36 Overall: 8.0% vs. 24%
(p < .02); type IIeIII:
2.0% vs. 14.0% (p < .01);
haematoma: 3.0% vs.
6.0% (NS)
30 days: 93.0% vs.
85.0% (NS)
Unknown Unknown
Johnson et al. (1998)38 6.2% (type I) vs. 31%
(type IeIII)
15/16 patent at 7
months, 1 occlusion
and 1 focal stenosis
and repaired under LA
Unknown Unknown
Robbins et al. (1998)37 Infection: 2.9% vs. 0%;
haematoma: 8.8% vs. 3.3%
0 vs. 1 Unknown Unknown
Jordan Jr et al. (1997)43 8.8% (type IeII), one
bleed in EVH tunnel
leading to haematoma
and prolonged LoS. In
OVH comparison 11.4%
Cumulative patency
(1e24 months):
65.3  8.0%
Unknown Cumulative patency
(0e24 months):
83.5  5.0%
Y.A. Jauhari, C.O.
Hughes, S.A. Black,
K.G. Jones, R.J.
Hinchliffe, M.M.
Thompson, P.J.
Holt, A. Karthikesalingam
(unpublished)
Harvest site (type I): 7.6% vs. 7.4% 30 days: 90.0  7.0%vs.
92.0  5.0% (NS); 6
months: 84.0  8.0%
vs. 80.0  12.0% (NS)
30 days: 95.0  5.0 vs. 96.0 
4.0%; 6 months: 95.0  5.0
vs. 83.0  12.0%
30 days: 95.0  5.0%
vs. 96.0%  4.0%;
6 months: 95.0 
5.0% vs. 83.0  12.0%
Note. NS ¼ not signiﬁcant; LoS ¼ length of stay; LEAB ¼ lower extremity arterial bypass; LA ¼ local anaesthetic.
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Tab 4. Secondary outcome. Results are presented as endoscopic vein harvest (EVH) versus open vein harvest (OVH).
S dy Procedure length (min) % Limb salvage LoS (mean d, range) Financial outcomes
S to et al. (2014)41 249 (192e325) vs. 316
(257e373) (p < .001)
60 months: 91.0% vs.
89.0% (NS)
7 (4e12) vs. 10 (7e17) (p < . In failed grafts, no signiﬁcant
difference in mean stenoses
or median stenosis length
W rtman et al. (2013)33 252  72 vs. 248  76 Unknown 6.6  7.5 vs. 7.7  5.2 (NS) Haemodialysis increased
loss of primary assisted
and secondary
E et al. (2012)34 Unknown Unknown EVH 7.14  9.7 vs. OVH 6.05 3 (NS) NA
Ju iard et al. (2011)20 Unknown (Approx.) 36 months:
80.0% vs. 72.0% (NS)
10 vs. 10 (NS) (median 7 vs. 9 NA
H es et al. (2010)45 Unknown Unknown Overall 4.9  5.7. In tissue lo
9.4  8.2 vs. claudicants 2.6 
and rest pain 2.6  0.7 (p < .
NA
Ji enez et al. (2007)42 410.4  123.7 12 months: 100.0% Unknown NA
P latt et al. (2006)21 Unknown 60 months: 59.0% vs.
58.0e73.0% (NS)
Unknown NA
T tter et al. (2006)35 Unknown At 10 months: 81% Unknown NA
G zoni et al. (2006)19 248  79 vs. 224  69 (NS) 21 months: 96.5% vs.
86.0% (NS)
6.3  3.9 vs. 6.5  4.9 (NS) NA
E oes et al. (2005)27 248 (163e375) 18 months: 90.8% 4.94 (1.0e35.0) NA
Il et al. (2003)39 Unknown 1 month: 98.0% vs.
98.0% (NS); 12 months:
86.0% vs. 83.0% (NS);
24 months: 83.0% vs.
83.0% (NS)
8.3  7.8 vs. 10.1  12.3 (p < ) Total cost: $6,203  3,326 vs.
$7,456  3,186 (p < .02);
non-ICU: $1,751  1,166
vs. $2,231  1,078 (p < .02);
imaging: $338  508 vs.
$681  732 (p < .005);
re-admission for wound
complication: $23,797
vs. $204,557
S gs et al. (2001)40 295  30 vs. 285  25 12 months: 94.0% 
5.0% vs. 92.0  3.0%
6.2  1 vs. 9.2  1 (p < .05) NA
Jo dan Jr et al. (2001)44 Unknown 60 months: 89.0% 8.1 (2.0e60.0) NA
Il et al. (2001)36 232  77 (95e285); vein
harvest time: 50  18 (25e90)
Unknown 7.7  5.7 vs. 9.4  12.6 (NS) Short stay duration:
EVH 4.0  2.4 vs.
OVH 6.0  3.2 days (p < .02)
Jo nson et al. (1998)38 Unknown At 7 months: EVH
100.0%; unknown for OVH
3.8 (1.5e12.0) vs. 6.15 (1.5e1 Cost of EVH equipment:
$1,178.33 þ reusable
equipment ¼ $3,743
R bins et al. (1998)37 188.0  46.9 vs. 158.0  36.5
(p [ .005)
100.0% 3.3  1.6 vs. 5.5  3.8 (p [ Patient charge $21,600  12,413
vs. $25,150 vs. 15,281 (NS)
Jo dan Jr et al. (1997)43 80.1 (vein harvest only) Unknown Overall 6.0 (3.0e60.0) (in wou
complications: 11.5)
LoS in wound
complications ¼ 11.5 d
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634 Y.A. Jauhari et al.LEAB for critical limb ischaemia.34,41 Other indications, such
as trauma, were included in three studies.19,20,27 Among the
comparative papers, Julliard et al.20 had a signiﬁcantly
higher proportion of patients with claudication (33.7% vs.
22.8%, p ¼ .03) and lower proportion of trauma (0.6% vs.
7.3%, p ¼ .001) in the EVH group.20 There was no other
signiﬁcant difference in the indication for LEAB in other
studies.
Primary outcome: patency
There was heterogeneity in the reporting and follow-up
periods of primary, primary assisted, and secondary
patency. Five of 18 comparative studies reported no sig-
niﬁcant difference in the patency of LEAB after EVH or
OVH.19,33,36,39 As shown in Table 3, no studies found a
signiﬁcant difference in limb salvage rates between the two
techniques. Four of 12 studies noted inferior patency rates
in EVH than in OVH at 12-, 36-, and 60-month follow-
up.20,21,34,41
In a limited HR meta-analysis of six comparative studies
(Fig. 4), there was a signiﬁcant difference in primary patency
rates for EVH compared with OVH with a pooled HR of
1.294 (95% conﬁdence interval [CI] 1.03e1.63;
p ¼ .028).19e21,28,39,46
Several studies performed subgroup patency analysis.
Julliard et al.20 found that in patients with diabetes and
limb-threatening ischaemia EVH had signiﬁcantly worse
patency rates than OVH (p < .01 and p < .001, respec-
tively). In Wartman et al.33 patients with a low body mass
index had poorer primary patency in EVH compared with
OVH (p ¼ .02 and p ¼ .15, respectively). They also found
inferior primary assisted patency rates in both EVH (p ¼ .02)
and OVH (p ¼ .02) in haemodialysis patients.
Primary outcome: wound complications
Wound complication rates varied from 4.0% to 36.7%, the
majority of which were type I or II (Table 3). A meta-analysis
of 12 comparative studies found no signiﬁcant improve-
ment in wound complication rates with EVH, with a pooled
relative risk 0.808 (95% CI 0.61e1.08; p ¼ .15) (Fig. 5).
Santo et al.41 found signiﬁcantly lower vein harvest incision
complications in EVH than in OVH (11.8% vs. 29.1%,
p ¼ .02), but there was no statistical signiﬁcance in the
overall wound complications between techniques.41 The
estimated cost-saving following lower readmission rates for
infection in the EVH group was $180,760 ($2,200 per pa-
tient).39 Non-infective wound complications included hae-
matoma (EVH 12/231 [5.2%] vs. OVH 19/270 [7.0%]);
seroma (EVH 7/108 [6.4%] vs. OVH 15/134 [10.9%]); and,
rarely, arteriovenous ﬁstula (n ¼ 1) and saphenous neu-
ralgia (n ¼ 1/150).36,37,39,43
Secondary outcomes (Table 4)
Operator experience varied from one senior vascular sur-
geon (6/18) to multiple at surgeons at different stages of
training (5/18) to cardiac or surgical physicians assistants (4/
18). Three studies did not acknowledge their EVH surgeons.
Figure 3. Outline of studies included in this review.
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 6 p. 621e639 June/2014 635The reported procedure times for EVH in LEAB ranged from
188.0 (46.9) to 410.0 (123.7) minutes. Robbins et al.37
had a signiﬁcantly longer procedure time for EVH
compared with OVH (188.0  46.9 vs. 158.0  36.5 minutes
[p ¼ .005]), but Santo et al.41 found that EVH took signiﬁ-
cantly less time than OVH (249.0 [192.0e325.0] vs. 316.0
[257.0e373.0] minutes; p < .001).
These time differences were not replicated in other
comparative studies. No studies clariﬁed whether the
procedure time included equipment set up. Therefore, a
pooled analysis of procedure times was not carried out.
Three studies declared the rate of intraoperative EVH
complications.27,36,44 The rate of vein repair and conver-
sion to open was 7/408 (1.7%) and 5/258 (1.9%),
respectively.
The cost-effectiveness of EVH in LEAB can be measured
directly, based on the cost of equipment and service, and
indirectly based on duration of hospital stay and primary
outcomes (patency and wound complications). Two
comparative studies evaluated the overall cost per pa-
tient.37,39 The results of these studies differed in the cost
per patient ($6,203  3,326 and $21,600  12,413), and
only one study showed a signiﬁcant reduction in cost in
comparison to OVH ($7,456  3,186) (p< .02). Twelve of 18
studies reported on comparative length of stay (LoS) in
hospital. There was no consensus on the impact of EVH on
LoS. Six of 12 studies cited signiﬁcantly shorter LoS in EVHcompared with OVH,37,39e41,45 while this difference was not
signiﬁcant in the other 6/12 studies.19,20,33,34,36,38 No
studies reported longer hospital stay after EVH.DISCUSSION
The main ﬁnding of this study was that EVH may reduce the
rate of primary patency in LEAB with no evidence of a dif-
ference in wound complication rates compared with OVH.
However, the available evidence was limited by evolution in
technology and the learning curve of EVH, which affects the
results owing to varying operator experience over time. The
existing evidence base was heterogeneous, scarce, and of
poor qualitydranging from level 3 (case-control studies) to
4 (case series).
Endothelial injury is potentially increased during EVH.
This is an important consideration in peripheral vascular
surgery as a longer length of good quality vein is required
for LEAB. A research series on the EVH learning curve found
that novice operators were more likely to cause endothelial
injury, which then results in blunted early positive remod-
elling and greater luminal loss.47 As the gradient of the EVH
learning curve remains unknown, the lack of detail
regarding operator experience should be regarded as an
important potential confounding factor affecting the avail-
able literature. Comparative studies have not demonstrated
a signiﬁcant difference in endothelial histological or
Figure 4. Forest plot illustrating wound complications.
636 Y.A. Jauhari et al.functional quality between EVH and OVH,10,48,49 but
focused study is required with clinical endpoints. The exis-
tence of a learning curve for EVH also has clinical conse-
quences for patients, as during this time conduits may be
lost and lead to revision with prosthetic grafting, explan-
tation without replacement, or limb loss.
Several studies in this review selected patients for EVH
based on “surgeon preference”. This is usually based on the
surgeon’s experience, and includes consideration of patient
habitus, previous trauma, and conduit quality, and could
represent a source of considerable selection bias.
In contrast to LEAB, there is extensive research on EVH
outcomes for CABG. A pooled analysis of randomised
controlled trials did not demonstrate a signiﬁcant increase
in graft failure after EVH, but the topic remains controver-
sial.12,50,51 However, there is consensus that EVH signiﬁ-
cantly reduces wound infection rates in CABG
patients.9,10,50
Although there are reports of infection rates of up to 30%
following OVH for both LEAB and CABG, there may be
several reasons why EVH did not reduce wound complica-
tions in the present meta-analysis of LEAB patients.4,9,37,46
Few studies in this review were powered to investigate
infection rates, and there is variability between the
reporting standards of infection between cardiothoracic and
vascular surgery. LEAB patients are at particularly high riskfor wound infection, irrespective of conduit harvest tech-
nique, with a high prevalence of speciﬁc risk factors for
wound infection, including preoperative ulceration and
diabetes mellitus.6,46 Julliard et al.20 proposed that EVH
should have a reduced role in patients with limb-
threatening disease and diabetes to reduce the effect of
microvascular disease on patency outcome.20 Unfortu-
nately, few other data exist to examine this potentially
important assertion.
There were few reports of other EVH wound complica-
tions in LEAB in our review. A recent meta-analysis on
wound complications in cardiothoracic surgery noted a
reduction in neuralgia and haematoma formation in EVH
compared with OVH.40 These results should be cautiously
applied to LEAB patients owing to differences in operative
practices and patient characteristics between specialities.
Furthermore, the common practice of compression
bandaging following vein harvest in cardiothoracic surgery
is usually discouraged in patients with peripheral vascular
disease owing to the increased risk of ischaemia.
This reasoning also applies in evaluating cost-
effectiveness between EVH and OVH in LEAB. Of the two
studies that looked at EVH cost, one found reduced cost
with EVH, and the other noted no overall cost difference
between the techniques.37,39 In the former, this was due to
reduced requirement in postoperative care and readmission
Figure 5. Forest plot of primary patency.
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review as only three studies described the postoperative
care employed (analgesia  epidural use and anti-platelet
therapy).19,21,38 A systematic review on cost-effectiveness
of EVH also found insufﬁcient evidence in current cardio-
thoracic and vascular surgery literature to make recom-
mendations on the ﬁnancial implications.29 Formal health
economic analysis is required.
CONCLUSION
EVH is associated with reduced primary patency rates after
LEAB, but does not demonstrate a clear advantage with
respect to postoperative wound complications. However,
the available data are heterogeneous and of poor quality.
Further uncertainty was introduced by evolutions in EVH
technology over time, the impact of variation in case se-
lection, and the effect of the learning curve on EVH out-
comes with increasing technical experience. There is a need
for a high-quality prospective study of EVH in LEAB with
modern equipment, experienced operators, deﬁned
reporting criteria, and strict inclusion criteria. EVH should
be used with caution in routine clinical practice and should
ideally be restricted to the context of formal research.
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